A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest-risk patients
- PDF / 852,956 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 24 Downloads / 159 Views
and Other Interventional Techniques
A novel biosynthetic scaffold mesh reinforcement affords the lowest hernia recurrence in the highest‑risk patients Mitchell J. Parker1 · Rachel C. Kim1 · Martin Barrio1 · Juan Socas1 · Lawrence R. Reed1 · Attila Nakeeb1 · Michael G. House1 · Eugene P. Ceppa1 Received: 26 May 2020 / Accepted: 16 September 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Introduction Patients with higher postoperative infection risk undergoing ventral hernia repair (VHR) have limited options for mesh use. Biosynthetic mesh is intended to utilize the durability of synthetic mesh combined with the biocompatibility of biologic mesh. We sought to assess the outcomes of a novel biosynthetic scaffold mesh for VHR in higher risk patients over a 12-month postoperative period. Methods Two cohorts of 50 consecutive patients who underwent VHR with TELA Bio OviTex biosynthetic or synthetic mesh were retrospectively compared. Endpoints included surgical site occurrence (SSO), readmission rate, and hernia recurrence following VHR at 12 months postoperatively. Results OviTex mesh placement was associated with higher risk Ventral Hernia Working Group (VHWG) distribution and more contaminated CDC wound class distribution compared to synthetic mesh placement (VHWG grade 3: 68% vs. 6%, p I: 70% vs. 6%, p
Data Loading...
